Jiang Qiu-Yu, Xue Ru-Yi
Department of Gastroenterology and Hepatology, Zhongshan Hospital, Shanghai Institute of Liver Disease, Fudan University, Shanghai 200032, China.
Department of Gastroenterology and Hepatology, Shanghai Baoshan District Wusong Central Hospital (Zhongshan Hospital Wusong Branch, Fudan University), Shanghai 200940, China.
World J Gastrointest Oncol. 2024 Mar 15;16(3):577-582. doi: 10.4251/wjgo.v16.i3.577.
We conducted a comprehensive review of existing prediction models pertaining to the efficacy of immune-checkpoint inhibitor (ICI) and the occurrence of immune-related adverse events (irAEs). The predictive potential of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in determining ICI effectiveness has been extensively investigated, while limited research has been conducted on predicting irAEs. Furthermore, the combined model incorporating NLR and PLR, either with each other or in conjunction with additional markers such as carcinoembryonic antigen, exhibits superior predictive capabilities compared to individual markers alone. NLR and PLR are promising markers for clinical applications. Forthcoming models ought to incorporate established efficacious models and newly identified ones, thereby constituting a multifactor composite model. Furthermore, efforts should be made to explore effective clinical application approaches that enhance the predictive accuracy and efficiency.
我们对现有的与免疫检查点抑制剂（ICI）疗效及免疫相关不良事件（irAE）发生相关的预测模型进行了全面综述。中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）在确定ICI疗效方面的预测潜力已得到广泛研究，而在预测irAE方面的研究则较为有限。此外，将NLR和PLR相互结合或与癌胚抗原等其他标志物联合使用的组合模型，相比单独的个体标志物具有更强的预测能力。NLR和PLR是具有临床应用前景的标志物。未来的模型应纳入已确立的有效模型和新发现的模型，从而构建一个多因素复合模型。此外，应努力探索提高预测准确性和效率的有效临床应用方法。
